NSABP 28--PACLITAXEL FOLLOWING DOXORUBICIN/CYCLOPHOSPHAMIDE IN BREAST CANCER

本研究的主要目的是确定4个周期的紫杉醇治疗是否 术后4个周期的阿霉素（A）和环磷酰胺 (C)将更有效地延长无病生存期和生存期， 在可手术乳腺癌患者中进行4个周期的术后AC 具有一个或多个组织学阳性腋窝淋巴结的癌症。 患者应无转移性疾病的证据，并应 接受乳房肿瘤切除术加腋窝淋巴结清扫术或 乳房切除术加腋窝淋巴结清扫术 分层后， 阳性腋窝淋巴结数量、他莫昔芬给药和 手术后，患者将被随机分配到两组中的一组。所有 两组接受肿块切除术的患者将接受术后 在完成指定化疗后以及 任何毒性都已消退。

The primary aim of this study is to determine whether 4 cycles of Taxol given after 4 cycles of postoperative Adriamycin (A) and cyclophosphamide (C) will more effectively prolong disease-free survival and survival than do 4 cycles of postoperative AC alone in patients with operable breast cancer who have one or more histologically positive axillary lymph nodes. Patients should have no evidence of metastatic disease and should have undergone either lumpectomy plus axillary node dissection or total mastectomy plus axillary node dissection. Following stratification by number of positive axillary nodes, tamoxifen administration, and type of surgery, patients will be randomly assigned to one of two groups. All patients in both groups who undergo lumpectomy will receive postoperative radiotherapy after completion of their assigned chemotherapy and after any toxicity has resolved.